On July 11, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune check point inhibitor (CPI) (Press release, BriaCell Therapeutics, JUL 11, 2025, View Source [SID1234654348]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data show a meaningful survival advantage in heavily pretreated metastatic breast cancer (MBC) patient subtypes:
Triple negative breast cancer (TNBC): median overall survival (OS) of 13.9 months vs. 11.8 months for antibody drug conjugate Trodelvy (sacituzumab govitecan-hziy) and 6.9 months single agent chemotherapy data. BriaCell’s median OS has improved from 11.4 months last reported at ASCO (Free ASCO Whitepaper) in June 2025 . 1
Hormone receptor positive (HR+): median overall survival (OS) of 17.3 months vs. 14.4 months for Trodelvy and 11.2 months in single agent chemotherapy data.
"We are thrilled to see our Bria-IMT regimen outperform established benchmarks like Trodelvy in TNBC and HR+ MBC patients," stated Dr. William V. Williams, BriaCell’s President and CEO. "BriaCell’s patients had failed a median of six prior therapies, underscoring the potential clinical impact of our novel immunotherapy. We look forward to validating these findings in our ongoing pivotal Phase 3 study with overall survival as its primary endpoint."
Table 1: Analysis of survival data for BriaCell’s Phase 2 study versus Trodelvy in MBC patient subsets
Breast Cancer
Type Treatment Median
# of prior
lines of
therapy Median
Overall
Survival
(months) Survival
rate at 6
months (%) Survival
rate at 12
months (%)
TNBC Bria-IMT plus CPI* 6 13.9 78 56
TNBC Trodelvy 1
(sacituzumab govitecan-hziy) 3** 11.8 80*** 49***
Single agent chemotherapy 3** 6.9 56*** 22***
HR+
Bria-IMT plus CPI* 6 17.3 90 61
HR+ Trodelvy 1
(sacituzumab govitecan-hziy) 4 14.4 83*** 61
Single agent chemotherapy 4 11.2 76*** 47
* Patients treated with the Phase 3 formulation
** Prior chemotherapy-containing regimens
*** Derived from published Kaplan-Meier curves see 1
Abbreviations:
TNBC: Triple-negative breast cancer (lacks the estrogen receptor, progesterone receptor, and lacks or has low levels of human epidermal growth factor receptor 2 (HER2))
As shown in table 1, median OS number with Bria-IMT is higher than that reported in the treatment arm of the ASCENT study (SG) for TNBC patients, and twice that reported in treatment of physician’s choice arm.
HR+ : hormone receptor-positive
The Phase 2 Bria-IMT study enrolled 54 heavily pre-treated metastatic breast cancer patients (median number of prior treatments = 6) who received the Bria-IMT regimen plus checkpoint inhibitor. Of these 54 patients, 37 received the same formulation currently being used in BriaCell’s ongoing pivotal Phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06072612 ). No Bria-IMT related discontinuations have been reported to date.